1. Home
  2. CRSP vs FCN Comparison

CRSP vs FCN Comparison

Compare CRSP & FCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • FCN
  • Stock Information
  • Founded
  • CRSP 2013
  • FCN 1982
  • Country
  • CRSP Switzerland
  • FCN United States
  • Employees
  • CRSP N/A
  • FCN N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • FCN Professional Services
  • Sector
  • CRSP Health Care
  • FCN Consumer Discretionary
  • Exchange
  • CRSP Nasdaq
  • FCN Nasdaq
  • Market Cap
  • CRSP 5.4B
  • FCN 5.5B
  • IPO Year
  • CRSP 2016
  • FCN 1996
  • Fundamental
  • Price
  • CRSP $54.32
  • FCN $168.15
  • Analyst Decision
  • CRSP Buy
  • FCN Hold
  • Analyst Count
  • CRSP 16
  • FCN 2
  • Target Price
  • CRSP $72.27
  • FCN $175.50
  • AVG Volume (30 Days)
  • CRSP 2.9M
  • FCN 334.4K
  • Earning Date
  • CRSP 08-04-2025
  • FCN 10-23-2025
  • Dividend Yield
  • CRSP N/A
  • FCN N/A
  • EPS Growth
  • CRSP N/A
  • FCN N/A
  • EPS
  • CRSP N/A
  • FCN 7.09
  • Revenue
  • CRSP $38,050,000.00
  • FCN $3,662,887,000.00
  • Revenue This Year
  • CRSP $28.31
  • FCN $1.42
  • Revenue Next Year
  • CRSP $268.05
  • FCN $6.21
  • P/E Ratio
  • CRSP N/A
  • FCN $23.73
  • Revenue Growth
  • CRSP N/A
  • FCN N/A
  • 52 Week Low
  • CRSP $30.04
  • FCN $151.75
  • 52 Week High
  • CRSP $71.13
  • FCN $231.65
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 45.78
  • FCN 51.87
  • Support Level
  • CRSP $51.80
  • FCN $167.17
  • Resistance Level
  • CRSP $61.44
  • FCN $170.70
  • Average True Range (ATR)
  • CRSP 2.79
  • FCN 3.13
  • MACD
  • CRSP -0.79
  • FCN -0.05
  • Stochastic Oscillator
  • CRSP 26.14
  • FCN 74.00

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About FCN FTI Consulting Inc.

FTI Consulting Inc is a firm that generates its sales by providing professional business advisory services to customers. The company operates through five segments, namely corporate finance, forensic and litigation consulting, economic consulting, technology, and strategic communications. The company generates the majority of its revenue from the Corporate finance segment. Customers of the company come from a wide array of sectors, including construction, energy and power, environmental, financial institutions, healthcare and life science, insurance, real estate and infrastructure, retail and consumer products, telecom, media, and technology. The majority of the company's revenue is derived from serving customers in the United States.

Share on Social Networks: